Docket No. SPSUP0100WOUS

IFW

Α

CI 3 0 7006 &

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In regatent	application	of
-------------	-------------	----

Āρ		

Sergey I. Chernysh et al.

Serial No:

10/585,715

Filed:

July 11, 2006

For:

ANTITUMORAL AND ANTIVIRAL PEPTIDES

Art Unit:

Not Yet Assigned

Examiner:

Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

(c)_

Sir:

directe copy of following copies require	ed to the patents of each listed doo ng application(s) of each cited U ement under 37	37 C.F.R. 1.97 and 1.98, and in compliance with 37 C.F.R. 1.56, the Office's attention is pending applications, publications and other information listed on the attached PTO-1449. Accument is enclosed, except for (a) those previously cited or submitted to the Office in the upon which this application relies for an earlier filing date under 35 U.S.C. 120, and (b). S. patent and each U.S. patent application publication in accordance with the waiver of the CFR 1.98(a)(2)(i) for submission of U.S. patent references in applications filed after June 30, the Official Gazette Notice dated 5 August, 2003.
	Serial No.: Filing Date:	
Applic althou	ant(s) believe(s)	ent, publication or other information for which a date is not given on the attached PTO-1449, the same may qualify as "prior" art to this application and should be treated accordingly, eserve(s) the right to contest the prior art status of any document, publication or information,
	panies this State	ach listed document that is not in the English language, an English-language translation ement as indicated on the attached PTO-1449 or a concise explanation of the relevance of the in the following document(s):
	(a)	A copy of each English language version of a search report (or EPO Search Report) indicating the degree of relevance found by the foreign office of each document being submitted from the search report, is being submitted herewith or has previously been submitted.
	(b)	Attached is a "Concise Explanation of Relevance of Non-English Language Documents".
3.	Pursuant to	37 C.F.R. 1.97(b) this Statement is being filed (one must be checked):
	(a)	Within 3 months of the filing date or date of entry into the National Stage.
	(b) <u>X</u>	Before the mailing date of a first Office Action on the merits. If this Statement is not filed before the mailing date of a first Office Action on the merits, the required certification is given below or, in the absence thereof, the Office is authorized to charge the required fee set forth in 37 C.F.R. 1.17(p) to Deposit Account No. 18-0988 for consideration of this

Before the mailing date of a first Office Action on the merits after a first or second

submission after final rejection under 37 C.F.R. 1.129(a).

	(d)	_	After the period set forth in 37 C.F.R. 1.97(b) but before the mailing date of either a final action or a notice of allowance.
		(1)	The required certification is given below, or
		(2)	Enclosed is a check covering the fee set forth in 37 C.F.R. 1.17(p) for consideration of this Statement, or
		(3)	Charge the fee set forth in 37 C.F.R. 1.17(p) to Deposit Account No. 18-0988
	(e)	_	After the mailing date of either a final action or a notice of allowance, but before payment of the issue fee. Petition hereby is made for consideration of this Statement and the required certification is indicated below.
		(1)	Enclosed is a check covering the fee set forth in 37 C.F.R. 1.17(p), or
		(2)	Charge the fee set forth in 37 C.F.R. 1.17(p) to Deposit Account No. 18-0988.
4	Certif	ication ((if applicable)
	(a)	_	The undersigned hereby certifies that each item of information contained in this Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than 3 months prior to the filing of this Statement.
	(b)	_	The undersigned hereby certifies that no item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the undersigned's knowledge after making reasonable inquiry, no item of information contained in this statement was known to any individual designated in 37 C.F.R. 1.56(c) more than 3 months prior to the filing of this Statement.
5. Deposit A			sioner is hereby authorized to charge any additional fees or credit any overpayment to 3-0988.
			Respectfully submitted,
		,	RENNER, OTTO, BOISSELLE & SKLAR, LLP
			By Heidi A. Boehlefeld, Reg. No. 34,296
1621 Euc			9th Floor
Clevelan (216) 62	-		5
			CERTIFICATE OF MAILING OR ELECTRONIC TRANSMISSION
X being	g depos nissione	sited with er for Pat	aper (along with any paper referred to as being attached or enclosed) is the United States Postal Service with sufficient postage for first class mail in an envelope addressed to tents address above. the USPTO Electronic Filing System.
Denise G.	. Bacht	<i>Dachter</i> el	October 24, 2006 Date

Form PTO-1449 (Modified) Atty Docket No. Serial No. SPSUP0100WOUS 10/585,715 LIST OF PATENTS AND PUBLICATIONS Applicant: FOR APPLICANT'S Sergey I. Chernysh et al. **ENFORMATION DISCLOSURE STATEMENT** Filing Date Group (Use several sheets if necessary) OCI 3 0 2006 07/11/2006 Not Yet Assigned LLS PATENT DOCUMENTS

		0.5.	FATERI DOCUMENTO			
Examiner	Document Number	Date (MM/YYYY)	Name	Class	Sub-class	Filing Date if Appropriate
	5,231,081	07/1993	Stiefel et al.	514	6	
	5,773,572	06/1998	Fishleigh et al.	530	324	

FOREIGN PATENT DOCUMENTS

Examiner	Document Number	Date	Country	Class	Sub- class	Translation	
Initial	•					Yes	No
	96/13590	9 May 1996	wo				
	01/77687	18 Oct. 2001	WO				
	0 668 350 B1	28.07.2004	EP				
	197 41 607 A 1	1999-03-25	DE			Abst	ract
	2 172 322 C1	2001-08-20	RU			Abst	ract

OTHER ART

Examiner Initial	Author, Title, Date, Pertinent Pages, etc.
	N. I. Perevodchikova, Clinic Chemotherapy of Tumor Diseases - in Russian, Moscow: Medicine, 1979, Pages 100-103.
	Zee et al., J. Clin. Oncol., 1998, 16, 8, Pages 2834-2839.
	Aviles et al., Leuk. Lymphoma, 1998, 30, 5-6, Pages 651-656 (Abstract).
	Gilbert, Cancer, 1998, 83, 6, Pages 1205-1213.
	Rutledge, Chin and Schepartz. Current Opinion in Chemical Biology, 2002, 6, Pages 479-485.
	S.K. Narula, R. Cofman, eds., New Cytokines as Potential Drugs, Birkhauser Verlag, Basel, 2000, Pages 68-69 and 89-90.
	Chernysh et al., Proceedings of National Academy of Science, 2002, 99, Pages 12628-12632.
	Kourie, J.I., Chem. Biol. Interact., 2001, 138, 1-26.
	Taylor, S.C., Green, K.N., Smith, I.F. & Peers, C. Am. J. Physiol. Cell Physiol., 2001, 281, 1850-1857.
	Mabbott, N.A., Brown, K.L., Manson, J. & Bruce, M.E., Immunology, 1997, 92, Pages 161-165.

EXAMINER	DATE CONSIDERED

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement PTO-1449 (Modified)

The identification of any reference is not intended to be, and should not be understood as being, an admission that such publication, in fact, constitutes "prior art" within the meaning of applicable law since, for example, a given reference may have a later effective date than first seems apparent or the reference may have an effective date which can be antedated. The "prior art" status of any reference is a matter to be resolved during prosecution.